Number of the records: 1
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
Title Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies Author info Salek T. ... [et al.] Co-authors Šálek Tomáš
Corporation Redakcia Onkológia
Note Cancers (Basel). 2022 Feb 24;14(5):1168 Sign. C 3069 Source Onkológia. - ISSN 1336-8176. - Bratislava : SOLEN , 2022 . - Roč. 17, č. 2 (2022), s. 139 MeSH Subject nádory žalúdka
adenokarcinóm
spojenie ezofagogastrické
paklitaxel
farmakoterapia kombinovaná
prežívanie bez progresie
Form, Genre abstrakt v angličtine
Subj. Headings adenokarcinóm žalúdka a ezofagogastrického spojenia metastatický/lokálne pokročilý * kombinácia ramucirumab a paklitaxel * vyhodnotenie súboru pacientov Language English Country Slovak Republic Document kind Rozpis článkov z periodík Database ARTICLES 
article
Number of the records: 1